Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma

Abstract

Survivin is expressed in neoplastic cells and appears to be associated with resistance to therapy and shorter survival in various types of tumours. The aim of the present study was to determine whether nuclear or cytoplasmic expression of survivin is related to disease recurrence and overall survival of patients with Stage I and II melanoma according to the American Joint Committee on Cancer (AJCC) staging system.\ud METHODS AND RESULTS:\ud Immunohistochemistry was performed on formalin-fixed paraffin-embedded sections of primary cutaneous melanoma from 50 patients. Survival rates were estimated using the Kaplan-Meier method and compared using the log rank test. Association of clinical variables (gender, age, tumour location, thickness, Clark level and AJCC stage) with survivin expression was analysed by Fisher's exact test. Patients with nuclear immunoreactivity for survivin had an increased risk of disease recurrence during the first three postoperative years (P < 0.05) and of death (P < 0.05). Cytoplasmic immunoreactivity was not correlated with either survival or clinical variables.\ud CONCLUSIONS:\ud Nuclear presence of survivin may be an independent biomarker for disease recurrence and overall survival in patients with Stage I and II melanoma

Immunohistochemical Detection of Survivin in Canine Lymphoma

“…The finding of survivin expression in epithelia of the placenta, gastrointestinal tract and skin are in agreement with multiple immunohistochemical studies of adult human and 29 rodent tissues (Chiodino et al, 1999;Gianani et al, 2001;Ding et al, 2006;Lechler et al, 2007;Piras et al, 2007) and with expression data available from a publicly accessible repository (http://www.proteinatlas.org/). Positive expression in several further organs including testis, kidney, liver and brain ( Kobayashi et al, 1999;Altura et al, 2003;Moon and Tarnawski, 2003;Lechler et al, 2007) is supported by at least one previous study with human tissues and by data from the protein atlas.…”

“…The majority of immunohistochemical studies on human tissues report use of polyclonal antibodies for detection of survivin, and these are considered to be more sensitive than monoclonal antibodies (Grossman et al, 1999;Ding et al, 2006;Vischioni et al, 2007). The polyclonal antibody used in the present study has been used previously to label survivin in human specimens (Martinez et al, 2004;Schlette et al, 2004;Ding et al, 2006;Piras et al, 2007;Vischioni et al, 2007) as well as in canine mastocytoma, urinary bladder transitional cell carcinoma and lymphoma (Scase et al, 2006;Rebhun et al, 2008;Velando Rankin et al, 2008). In two of the latter studies (Scase et al, 2006;Rebhun et al, 2008), antibody specificity was confirmed by western blot analysis.…”

Apolipoprotein A-I: A Molecule of Diverse Function

“…However, apo A-I also suppresses this increase of MDSCs, both within and outside the tumor and help in tumor regression [15,43]. Not only that, apo A-I also causes decline in survivin, an inhibitor of apoptosis and cell cycle promoter, responsible for recurrence and reduced survival in melanoma, as shown by Piras et al [47] (Fig. 4) [15,43,47].…”

“…Not only that, apo A-I also causes decline in survivin, an inhibitor of apoptosis and cell cycle promoter, responsible for recurrence and reduced survival in melanoma, as shown by Piras et al [47] (Fig. 4) [15,43,47].…”

Survivin in breast lesions: immunohistochemical analysis of 196 cases

“…It is undetectable in most terminally differentiatednormalcells,butitisabundantinembryonicandfetaltissuesaswellasinamajorityofhuman malignancies including breast carcinomas [6]. Survivinisamultifunctionalproteinthatcontrolscell divisionandinhibitionofapoptosisaswellasenhancesangiogenesis [7].Itisalsooneofthechromosome passenger proteins and plays an important role in mitosisandspindlecheckpoints [8].Survivinshuttles between nucleus and the cytoplasm and hence, canbeassociatedwithdifferentsubcellularcompartments [1,9].Duetolargequantitativedifferencein thelevelofsurvivinexpressioninmalignanttumors on the one hand, and in corresponding normal tissueontheotherhand,survivinappearstorepresent a promising prognostic biomarker [10]. The prognosticvalueofsurvivinexpressionisamatterofdiscussion.Forbreastcancerpatients,itsprognosticrole has been reported either nonexistent [9,11,12] or associatedwithanimproved [13]oradverseoutcome [7,14,15].…”